Dosing Recommendations for Lamotrigine in Children : Evaluation Based on Previous and New Population Pharmacokinetic Models
© 2020, The American College of Clinical Pharmacology..
Lamotrigine is a broad-spectrum antiepileptic drug with high interindividual variability in serum concentrations in children. The aims of this study were to evaluate the predictive performance of pediatric population pharmacokinetic (PPK) models published on lamotrigine, to build a new model with our monitoring data and to evaluate the current recommended doses. A validation cohort included patients treated with lamotrigine who had a serum level assayed during therapeutic drug monitoring (TDM). PPK models published in the literature were first applied to the validation cohort. We assessed their predictive performance using mean prediction errors, root mean squared errors, and visual predictive checks. A new model was then built using the data. Dose simulations were performed to evaluate the doses recommended. We included 270 lamotrigine concentrations ranging from 0.5 to 17.9 mg/L from 175 patients. The median (range) age and weight were 11.8 years (0.8-18 years) and 32.7 kg (8-110 kg). We tested 6 PPK models; most had acceptable bias and precision but underestimated the variability of the cohort. We built a 1-compartment model with first-order absorption and elimination, allometric scaling, and effects of inhibitor and inducer comedications. In our cohort, 22.6% of trough concentrations were below 2.5 mg/L. In conclusion, we proposed a PPK model that can be used for TDM of lamotrigine in children. In our population, a high percentage of children had low trough concentrations of lamotrigine. As the intervals of recommended doses are large, we suggest aiming at the higher range of doses to reach the target concentration.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Journal of clinical pharmacology - 61(2021), 5 vom: 26. Mai, Seite 677-687 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tauzin, Manon [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticonvulsants |
|---|
| Anmerkungen: |
Date Completed 20.12.2021 Date Revised 20.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jcph.1791 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318112477 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318112477 | ||
| 003 | DE-627 | ||
| 005 | 20231225164655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jcph.1791 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1060.xml |
| 035 | |a (DE-627)NLM318112477 | ||
| 035 | |a (NLM)33244764 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tauzin, Manon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dosing Recommendations for Lamotrigine in Children |b Evaluation Based on Previous and New Population Pharmacokinetic Models |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.12.2021 | ||
| 500 | |a Date Revised 20.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020, The American College of Clinical Pharmacology. | ||
| 520 | |a Lamotrigine is a broad-spectrum antiepileptic drug with high interindividual variability in serum concentrations in children. The aims of this study were to evaluate the predictive performance of pediatric population pharmacokinetic (PPK) models published on lamotrigine, to build a new model with our monitoring data and to evaluate the current recommended doses. A validation cohort included patients treated with lamotrigine who had a serum level assayed during therapeutic drug monitoring (TDM). PPK models published in the literature were first applied to the validation cohort. We assessed their predictive performance using mean prediction errors, root mean squared errors, and visual predictive checks. A new model was then built using the data. Dose simulations were performed to evaluate the doses recommended. We included 270 lamotrigine concentrations ranging from 0.5 to 17.9 mg/L from 175 patients. The median (range) age and weight were 11.8 years (0.8-18 years) and 32.7 kg (8-110 kg). We tested 6 PPK models; most had acceptable bias and precision but underestimated the variability of the cohort. We built a 1-compartment model with first-order absorption and elimination, allometric scaling, and effects of inhibitor and inducer comedications. In our cohort, 22.6% of trough concentrations were below 2.5 mg/L. In conclusion, we proposed a PPK model that can be used for TDM of lamotrigine in children. In our population, a high percentage of children had low trough concentrations of lamotrigine. As the intervals of recommended doses are large, we suggest aiming at the higher range of doses to reach the target concentration | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a dosing | |
| 650 | 4 | |a lamotrigine | |
| 650 | 4 | |a pediatrics | |
| 650 | 4 | |a population pharmacokinetics | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a Lamotrigine |2 NLM | |
| 650 | 7 | |a U3H27498KS |2 NLM | |
| 700 | 1 | |a Tréluyer, Jean-Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Nabbout, Rima |e verfasserin |4 aut | |
| 700 | 1 | |a Billette de Villemeur, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Desguerre, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Aboura, Radia |e verfasserin |4 aut | |
| 700 | 1 | |a Gana, Ines |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Benaboud, Sihem |e verfasserin |4 aut | |
| 700 | 1 | |a Bouazza, Naim |e verfasserin |4 aut | |
| 700 | 1 | |a Chenevier-Gobeaux, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Freihuber, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Hirt, Déborah |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical pharmacology |d 1973 |g 61(2021), 5 vom: 26. Mai, Seite 677-687 |w (DE-627)NLM000005576 |x 1552-4604 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2021 |g number:5 |g day:26 |g month:05 |g pages:677-687 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jcph.1791 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2021 |e 5 |b 26 |c 05 |h 677-687 | ||